Key result
Epicardial VT ablation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia after failed endocardial ablation resulted in no VT in 77% of patients over 18±13 months.
Why the study?
Does epicardial VT ablation prevent VT recurrence in patients with ARVC/D who failed endocardial ablation?
Observational (n=13)
Does epicardial VT ablation prevent VT recurrence in patients with ARVC/D who failed endocardial ablation?
Epicardial VT ablation is effective for VT control in ARVC/D patients who failed endocardial ablation, as these patients have extensive epicardial arrhythmogenic substrate.
May support epicardial ablation after endocardial failure in ARVC/D; case-report data leave efficacy unconfirmed.
Background— Efficacy of endocardial ventricular tachycardia (VT) ablation in arrhythmogenic right ventricular cardiomyopathy/dysplasia may be limited by epicardial VT, right ventricular thickening, or both. We sought to characterize the endocardial versus epicardial substrate, measure right ventricular free wall thickness, and determine epicardial ablation efficacy in patients with right ventricular cardiomyopathy/dysplasia. Methods and Results— Thirteen consecutive patients (3 female; aged 43±15 years; range, 17 to 70 years) undergoing endocardial and epicardial sinus rhythm voltage mapping and epicardial VT ablation after failed endocardial VT ablation were included. In each patient, the low bipolar voltage area (<1.0 mV for epicardium and <1.5 mV for endocardium) was more extensive on the epicardium (95±47 versus 38±32 cm 2 ; P <0.001) and was uniformly marked by multicomponent and late electrograms. The basal right ventricular thickness assessed by electroanatomic map was >10 mm in 6 of 13 patients compared with 5 to 10 mm in 4 reference patients without structural disease. Twenty-seven VTs were targeted on the epicardium with the use of activation, entrainment, or pace mapping with focal/linear ablation and targeting of late potentials. Epicardial VTs were targeted opposite normal endocardium in 10 patients (77%) and/or opposite ineffective endocardial ablation sites in 11 patients (85%). During 18±13 months, 10 of the 13 patients (77%) had no VT, with 2 patients having only a single VT at 2 and 38 months, respectively. Conclusions— Patients with right ventricular cardiomyopathy/dysplasia and VT after endocardial ablation have a more extensive epicardial area of electrogram abnormalities and frequently have basal right ventricular wall thickening. Epicardial substrate and VT mapping identifies targets, and ablation results in VT control.
No takes yet. Share an insight, caveat, or question.
García et al. (2009) conducted an observational in Arrhythmogenic right ventricular cardiomyopathy/dysplasia with ventricular tachycardia (n=13). Epicardial VT ablation was evaluated on Freedom from VT. Epicardial VT ablation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia after failed endocardial ablation resulted in no VT in 77% of patients over 18±13 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: